UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

Latest from UCLA Health Jonsson Comprehensive Cancer Center


Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

January 16, 2021

Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Shaping a New Future With Novel Therapeutics in Gynecologic Cancers

October 31, 2020

Ritu Salani, MD, MBA, discusses updates to PARP inhibition and FRα-targeting agents in ovarian cancer, the role of bevacizumab across all lines of ovarian cancer therapy, and immunotherapy highlights in cervical and endometrial cancer.

Some Types of Prostate Cancer May Not be as Aggressive as Originally Thought

June 04, 2020

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyze gene-expression patterns in the most aggressive prostate cancer grade group—known as Gleason grade group 5—and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences.

Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology

May 28, 2020

In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.

Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial

May 14, 2020

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

Chasing a Cure for GBM: Investigators Test Multiple Regimens in Novel Trial

May 14, 2020

Investigators of the first global adaptive phase 2/3 GBM Adaptive Global Innovative Learning Environment platform trial are implementing a multiarm, 2-stage approach to concurrently evaluate single-agent and combination regimens in glioblastoma.

x